head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing
ISSN: 1312-773X (Online)
Issue: 2017, vol. 23, issue 3
Subject Area: Medicine
DOI: 10.5272/jimab.2017233.1641
Published online: 04 August 2017

Original article

J of IMAB 2017 Jul-Sep;23(3):1641-1645
Negrin Negrev1ORCID logo, Kiril Hristosov2, Antoniya Hachmeryan1ORCID logo, Yuri Nyagolov3ORCID logo Corresponding Autoremail,
1) Department of Physiology, Medical University, Varna, Bulgaria
2) Department of Internal Diseases, Medical University, Varna, Bulgaria
3) Department of Physiology, Medical University, Sofia, Bulgaria.

Thymus peptides (thymulin, thymosin alpha 1 and thymosin beta 4) inhibiting effects on the intrinsic blood coagulation pathway in rats
Background and purpose: Hemostasis is a basic homeostatic mechanism protecting the body from thrombosis or haemorrhage. A number of pathological conditions, including multiple endocrine disorders modulate the balance between pro- and anticoagulation factors and establish conditions of hyper- or hypocoagulability. Endocrine effects of thymus gland on blood coagulation are not completely elucidated, and data existing on the theme are relatively scarce and partially controversial. The present study was designed to investigate thymus peptides (thymulin, thymosin alpha 1 and thymosin beta 4) effects on key intrinsic pathway plasma clotting factors XII, XI, IX, X and activated partial thromboplastin time (aPTT) – a principal marker of blood coagulation via intrinsic pathway of hemocoagulation, in rats.
Materials and methods: Plasma clotting factor activities and aPTT were studied on 52 male Wistar intact rats after 3 day s.c. application of the thymic peptides envisaged using routine kinetic coagulometry.
Results of the study indicate a significant reduction of FXII activity by thymulin and thymosin alpha 1, and FXI and FIX activity by thymulin and thymosin beta 4.
Conclusion: Upper results support the conclusion that thymus peptides thymulin, thymosin alpha 1 and thymosin beta 4 application in rats imposes a distinct tendency of hypocoagulability.

Keywords: thymulin, thymosin alpha 1, thymosin beta 4, aPTT, intrinsic pathway, hemocoagulation,

pdf - Download FULL TEXT /PDF 931 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Negrev N, Hristosov K, Hachmeryan A, Nyagolov Y. Thymus peptides (thymulin, thymosin alpha 1 and thymosin beta 4) inhibiting effects on the intrinsic blood coagulation pathway in ratsy. J of IMAB. 2017 Jul-Sep;23(3):1641-1645. DOI: 10.5272/jimab.2017233.1641

Corresponding AutorCorrespondence to: Yuri P. Nyagolov, Assoc. prof., MD, PhD. Department of Physiology, Medical University, Sofia, Bulgaria; E-mail: nyagolv@abv.bg

1. Davidson CJ, Hirt RP, Lal K, Snell P, Elgar G, Tuddenham EG, et al. Molecular evolution of the vertebrate blood coagulation network. Thrombo Haemost. 2003 Mar;89(3):420-8. [PubMed]
2. Versteeg HH, Heemskerk J, Levi M, Reitsma P. New Fundamentals in Hemostasis. Physiol Rev.  2013 Jan;93(1):327-58 [PubMed] [CrossRef]
3. Dahlback B. Blood coagulation. Lancet. 2000 May 6;355(9215):1627-32. [PubMed] [CrossRef]
4. Long AT, Kenne E, Jung R, Fuchs T, Renné T. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thrombosis Hemost. 2016 Mar;14(3) 427-37. [PubMed] [CrossRef]
5. Cheng Q, TuckerEI, Pine MS, Sisler I, Matafonov A, Sun MF, et al. A role for factor XIIa-mediated factor XI activation inthrombus formation in vivo. Blood. 2010 Nov 11;116(19):3981-9. [PubMed] [CrossRef]
6. Naudin C, Burillo E, Blankenberg S, Butler L, Renne T. Factor XII Contact Activation. Semin. Thromb. Hemostasis 2017 Mar 27, 0036. [PubMed] [CrossRef]
7. Gailani D, Renné T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2507-13. [PubMed] [CrossRef]
8. Soff GA. A new generation of oral direct anticoagulants. Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):569-74. [PubMed] [CrossRef]
9. Meijers J, Tekelenburg W, Bouma B, Bertina R, Rosendaal F. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000 Mar 9;342(10):696-701. [PubMed] [CrossRef]
10. Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. Ann Intern Med. 2003 Feb 4;138(3):W15-24. [PubMed]
11. Sié P, Steib A. Central laboratory and point of care assessment of perioperative hemostasis. Can J Anaesth. 2006 Jun;53(6 Suppl):S12-20. [PubMed]
12. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med. 2001 Jul;29(7 Suppl):S99-106. [PubMed]
13. Squizzato A, Gerdes V, Ageno W, Buller HR. The coagulation system in endocrine disorders: a narrative review. Intern Emerg Med. 2007 Jun;2(2):76-83. [PubMed] [CrossRef]
14. Franchini M, Lippi G, Manzato F, Vescovi PP, Targher G. Hemostatic abnormalities in endocrine and metabolic disorders. European J Endocrinol. 2010 Mar;162(3):439-51. [PubMed] [CrossRef]
15. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005 Sep;11(9):421-9. [PubMed] [CrossRef]
16. Renné T. The factor XII-driven plasma contact system. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Editors: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC II. Lippincott Williams & Wilkins. November 26, 2012. Chapter 15B: 120 p.
17. Lozier JN, Kessler CM. Clinical aspects and therapy of hemophilia. In: Hematology: Basic Principles and Practice. Editors: Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P. New York: Churchill Livingstone. 2005. p.2047.
18. Kaplan AP. Intrinsic coagulation, thrombosis, and bleeding. Blood. 1996; 87(5):2090.
19. Palta S, Saroa R, Palta U. Overview of the coagulation system. Indian J Anaesth. 2014 Sep-Oct; 58(5): 515–523. [PubMed] [CrossRef]
20. d’Audigier C, Delassasseigne C, Robert A, Eschwège V. Underestimation of plasma level of factor V coagulant activity and fibrinogen concentration together with prolonged prothrombin time, activated partial thromboplastin time and thrombin time can result from pre-analytical very low calcium level in citrated sample tube. Int J Lab Hematol. 2016 Feb;38(1):50-3. [PubMed] [CrossRef].

Received: 22 May 2017
Published online: 04 August 2017

back to Online Journal